文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

阿奇霉素联合标准治疗对比单用标准治疗用于巴西重症COVID-19住院患者(COALITION II):一项随机临床试验

Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
PubMed 文献 · Lancet · 2020-09-05
一句话结论重症COVID-19住院患者中,在含羟氯喹的标准治疗基础上加用阿奇霉素未改善第15天临床状态,作者不支持下述常规联合使用。

COALITION II是一项在巴西57个中心开展的非盲随机临床试验,纳入447例疑似或确诊COVID-19且至少满足一项额外严重度标准(氧疗流量>4 L/min、经鼻高流量氧疗、无创机械通气或有创机械通气)的住院患者,1:1随机分配至阿奇霉素500 mg每日一次(口服、鼻胃管或静脉给药)共10天联合标准治疗组或不用大环内酯类的标准治疗组,所有患者均接受羟氯喹400 mg每日两次共10天。主要终点为随机后第15天以六分量表评估的临床状态,在397例经分子或血清学确诊的改良意向治疗人群中,阿奇霉素组与对照组无显著差异(OR 1.36,95%CI 0.94-1.97,p=0.11)。不良事件包括临床相关室性心律失常、复苏后心脏骤停、急性肾衰竭和校正QT间期延长,两组间无显著差异。作者结论为在重症COVID-19患者中,在含羟氯喹的标准治疗基础上加用阿奇霉素未改善临床结局,不支持下述常规联合使用。

要点

  • 在397例确诊重症COVID-19的改良意向治疗人群中,阿奇霉素组与对照组第15天六分量表临床状态无显著差异(OR 1.36,95%CI 0.94-1.97,p=0.11)。
  • 所有患者均接受羟氯喹400 mg每日两次共10天作为巴西重症COVID-19标准治疗的一部分。
  • 阿奇霉素用法为500 mg每日一次,口服、鼻胃管或静脉给药,共10天。
  • 不良事件包括临床相关室性心律失常、复苏后心脏骤停、急性肾衰竭和校正QT间期延长,两组间无显著差异。
  • 作者结论为不支持下述在重症COVID-19患者中常规联合使用阿奇霉素与羟氯喹。

适用人群与场景

  • 纳入疑似或确诊COVID-19且至少满足一项额外严重度标准的住院患者:氧疗流量>4 L/min、经鼻高流量氧疗、无创机械通气或有创机械通气。
  • 改良意向治疗人群为随机前经分子或血清学检测确诊SARS-CoV-2感染的397例患者,其中阿奇霉素组214例、对照组183例。

诊断标准与关键阈值

  • 主要终点为随机后第15天以六分量表评估的临床状态,量表分值1至6分,分值越高病情越差,OR大于1.00倾向于对照组。

处置流程与药物剂量

  • 阿奇霉素500 mg每日一次,口服、鼻胃管或静脉给药,共10天,联合标准治疗。
  • 所有患者接受羟氯喹400 mg每日两次,共10天。

研究设计与关键结果

  • 研究类型为在巴西57个中心开展的非盲随机临床试验,2020年3月28日至5月19日共纳入447例患者。
  • 改良意向治疗人群397例(阿奇霉素组214例、对照组183例),主要终点第15天六分量表临床状态两组无显著差异(OR 1.36,95%CI 0.94-1.97,p=0.11)。
  • 不良事件包括临床相关室性心律失常、复苏后心脏骤停、急性肾衰竭和校正QT间期延长,两组间无显著差异。

证据类型、等级与局限

  • 证据类型:非盲随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论为在重症COVID-19患者中,在含羟氯喹的标准治疗基础上加用阿奇霉素未改善临床结局,不支持下述常规联合使用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain. We assessed whether adding azithromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of patients admitted to the hospital with severe COVID-19.

METHODS: We did an open-label, randomised clinical trial at 57 centres in Brazil. We enrolled patients admitted to hospital with suspected or confirmed COVID-19 and at least one additional severity criteria as follows: use of oxygen supplementation of more than 4 L/min flow; use of high-flow nasal cannula; use of non-invasive mechanical ventilation; or use of invasive mechanical ventilation. Patients were randomly assigned (1:1) to azithromycin (500 mg via oral, nasogastric, or intravenous administration once daily for 10 days) plus standard of care or to standard of care without macrolides. All patients received hydroxychloroquine (400 mg twice daily for 10 days) because that was part of standard of care treatment in Brazil for patients with severe COVID-19. The primary outcome, assessed by an independent adjudication committee masked to treatment allocation, was clinical status at day 15 after randomisation, assessed by a six-point ordinal scale, with levels ranging from 1 to 6 and higher scores indicating a worse condition (with odds ratio [OR] greater than 1·00 favouring the control group). The primary outcome was assessed in all patients in the intention-to-treat (ITT) population who had severe acute respiratory syndrome coronavirus 2 infection confirmed by molecular or serological testing before randomisation (ie, modified ITT [mITT] population). Safety was assessed in all patients according to which treatment they received, regardless of original group assignment. This trial was registered at ClinicalTrials.gov, NCT04321278.

FINDINGS: 447 patients were enrolled from March 28 to May 19, 2020. COVID-19 was confirmed in 397 patients who constituted the mITT population, of whom 214 were assigned to the azithromycin group and 183 to the control group. In the mITT population, the primary endpoint was not significantly different between the azithromycin and control groups (OR 1·36 [95% CI 0·94-1·97], p=0·11). Rates of adverse events, including clinically relevant ventricular arrhythmias, resuscitated cardiac arrest, acute kidney failure, and corrected QT interval prolongation, were not significantly different between groups.

INTERPRETATION: In patients with severe COVID-19, adding azithromycin to standard of care treatment (which included hydroxychloroquine) did not improve clinical outcomes. Our findings do not support the routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19.

FUNDING: COALITION COVID-19 Brazil and EMS.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020. PMID: 32896292. doi:10.1016/S0140-6736(20)31862-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。